AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06528496
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor
Trial: NCT06528496
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide is administered intravenously
Trial: NCT05006716
Drug: BGB-16673
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered
Trial: NCT06132867
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib oral solution
Trial: NCT06132867
Drug: Brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brigatinib tablet
Trial: NCT05162755
Drug: S95029 and Sym021
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.
Trial: NCT06462014
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: relugolix
Trial: NCT06229912
Drug: Revumenib
RxNorm normalized name: Revumenib
DrugBank: Revumenib (DB18515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06164314
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation
Trial: NCT05845450
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab deruxtecan 5.4 mg/kg IV on day 1
Trial: NCT05845450
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: durvalumab 1500 mg IV on day 1
Trial: NCT05845450
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: panitumumab 6 mg/kg IV on days 1 and 15
Trial: NCT05845450
Drug: Botensilimab
RxNorm normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: botensilimab 1 mg/kg on day 1
Trial: NCT05845450
Drug: Balstilimab
RxNorm normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: balstilimab 3 mg/Kg on days 1 and 15
Trial: NCT05845450
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sotorasib 960 mg orally once daily from day 1 to 28
Trial: NCT05365581
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenously
Trial: NCT05365581
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously
Trial: NCT05365581
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenously
Trial: NCT05365581
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenously
Trial: NCT05365581
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenously
Trial: NCT06504381
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06783153
Drug: Rifaximin 550 MG
RxNorm normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
Trial: NCT06430541
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
Trial: NCT06786689
Drug: Betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Betamethsone 5mg for 2 consecutive days weekly
Trial: NCT06465719
Drug: Hemocoagulase Bothrops Atrox for Injection；Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal ganglion hemorrhage patients will be managed with guideline-based medications without surgery. Hemocoagulase Bothrops Atrox for Injection belongs to the drug class of Hemostatic Agents. Nicardipine is a calcium channel blocker (CCB) drug to control blood pressure.
Trial: NCT05478603
Drug: PF-07081532
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
Trial: NCT05139901
Drug: Dornase Alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalations twice daily
Trial: NCT05139901
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalations twice daily
Trial: NCT05081882
Drug: Kava
RxNorm normalized name: kava
DrugBank: Kava (DB01322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
Trial: NCT05013255
Drug: Pioglitazone 15mg
RxNorm normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PIO 15mg orally once daily for 2 weeks
Trial: NCT05013255
Drug: Pioglitazone 30 mg
RxNorm normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PIO 30mg orally once daily for 2 weeks
Trial: NCT05861050
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05861050
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06105151
Drug: VV119(SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
Trial: NCT06105151
Drug: VV119(FE)
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A：4 mg VV119, following an overnight fast of at least 10 hours for Period 1; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 2; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 3; B: 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1; 4 mg VV119, following an overnight fast of at least 10 hours for Period 2; 4mg VV119, administered 30 minutes after the start of a standard meal for Period 3; C: 4mg VV119, administered 30 minutes after the start of a standard meal for Period 1; 4mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2;4 mg VV119, following an overnight fast of at least 10 hours for Period 3.
Trial: NCT04725695
Drug: Viscous Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will be randomized to either viscous lidocaine or placebo
Trial: NCT06529250
Drug: HAD
RxNorm normalized name: 4-OHAD
DrugBank: Formestane (DB08905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment.
Trial: NCT06529250
Drug: Daunorubicin+Cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment.
Trial: NCT04816461
Drug: Amodiaquine Sulfadoxine-Pyrimethamin administration
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SMC treatment
Trial: NCT04816461
Drug: Dihydroartemisinin-Piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roommates treatment if they are positive to malaria
Trial: NCT05688111
Drug: Tranexamic acid injection
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
Trial: NCT06050317
Drug: Sintilimab Plus mFFN and Radiation
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab Plus mFFN and Radiation
Trial: NCT06413537
Drug: SPG601
RxNorm normalized name: SPG601
DrugBank: SPG601 (DB18742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic small molecule
Trial: NCT06390995
Drug: TAK-853
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-853 intravenous injection
Trial: NCT06494995
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a PD-1/CTLA-4 dual antibody
Trial: NCT06396585
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W
Trial: NCT06396585
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive anlotinib,12mg, qd，d1-d14，Q3W
Trial: NCT06396585
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W
Trial: NCT06396585
Drug: Tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W
Trial: NCT05954143
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
Trial: NCT06283927
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Re-challenge Temozolomide chemotherapy
Trial: NCT06283927
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second line chemotherapy with Lomustine
Trial: NCT04781777
Drug: insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sonar guided insulin combined with dexamethasone and local anesthetics
Trial: NCT06563245
Drug: Brentuximab Vedotin for Injection
RxNorm normalized name: Brentuximab Vedotin for Injection
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.8mg/kg/dose (MAX 180 mg)
Trial: NCT06563245
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 125 mg/m2/dose
Trial: NCT06563245
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2, BID, orally
Trial: NCT06563245
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.
Trial: NCT06563245
Drug: Tislelizumab Injection
RxNorm normalized name: tislelizumab Injection
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
Trial: NCT04342962
Drug: tagraxofusp
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
Trial: NCT06562946
Drug: Pimicotinib
RxNorm normalized name: Pimicotinib
DrugBank: Pimicotinib (DB18972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
Trial: NCT04709029
Drug: Dexamethasone intravenous
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evaluation of intravenous dexamethazone in prevention of postdural puncture headache
Trial: NCT04709029
Drug: Dexamethasone intrathecal
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache
Trial: NCT05092451
Drug: Fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT04861064
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.
Trial: NCT04623216
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine comes in Vial for IV infusion or subcutaneous administration
Trial: NCT06514261
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT06514261
Drug: Iadademstat
RxNorm normalized name: Iadademstat
DrugBank: ORY-1001 (DB16848)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06514261
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05048238
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
Trial: NCT06041789
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet
Trial: NCT04667143
Drug: Retagliptin, Henagliflozein, metformin XR
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Retagliptin-DPP4 inhibitor Henagliflozein-SGLT-2 inhibitor Metformin XR
Trial: NCT06065748
Drug: Giredestrant
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Trial: NCT06065748
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
Trial: NCT06065748
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
Trial: NCT06065748
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
Trial: NCT06065748
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
Trial: NCT04720261
Drug: Caplacizumab
RxNorm normalized name: caplacizumab
DrugBank: Caplacizumab (DB06081)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
Trial: NCT06245551
Drug: Budesonide/albuterol metered-dose inhaler 160/180 μg
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)
Trial: NCT05286970
Drug: AK115
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abdominal subcutaneous injection
Trial: NCT03590821
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: timed administration of aspirin in the evening
Trial: NCT04947020
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin use before operation due to previously diagnosed diabetes.
Trial: NCT05900531
Drug: K-757 and open-label sitagliptin
RxNorm normalized name: sitagliptin and ertugliflozin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: both administered orally
Trial: NCT05900531
Drug: Matching placebo to K-757, open-label sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: both administered orally
Trial: NCT04951817
Drug: Ga-68 PSMA ligand
RxNorm normalized name: PSMA-11 Ga 68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For PET/CT PSMA scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later.PSMA PET-CT scan was performed on a GE Discovery MI PET/CT system.
Trial: NCT06702345
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral vancomycin pretreatment, 4 times a day 250mg, given the five days before toxigenic C. difficile exposure.
Trial: NCT06701760
Drug: Sodium Lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium lactate